Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. - Wikidata - awgldk - TriplyDB

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.

http://www.wikidata.org/entity/Q43701894

about

Mepolizumab versus placebo for asthma Omalizumab for asthma in adults and children Anti-IgE for chronic asthma in adults and children Anti-IgE for chronic asthma in adults and children Update in asthma 2009 Toll-Like Receptor 7-Targeted Therapy in Respiratory Disease Challenges and Current Efforts in the Development of Biomarkers for Chronic Inflammatory and Remodeling Conditions of the Lungs Airway fibrinogenolysis and the initiation of allergic inflammation HIV and asthma, is there an association?A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma Personalized Medicine in Allergy Development of New Therapies for Severe Asthma Therapeutic interventions in severe asthma Biologics in asthma--the next step toward personalized treatment Monoclonal antibodies and other biologic agents in the treatment of asthma Temporal Regulation by Innate Type 2 Cytokines in Food Allergies.The immunology of asthma: Asthma phenotypes and their implications for personalized treatment.Targeting patients with asthma for omalizumab therapy: choosing the right patient to get the best value for money.Asthma outcomes: exacerbations Omalizumab: a novel therapy for allergic asthma.IL4R alpha mutations are associated with asthma exacerbations and mast cell/IgE expression.Investigating lung responses with functional hyperpolarized xenon-129 MRI in an ex vivo rat model of asthma Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review B cell antigen presentation promotes Th2 responses and immunopathology during chronic allergic lung disease The Saudi Initiative for Asthma.The role of omalizumab in the treatment of severe allergic asthma.Relevance of allergy in adult asthma.Reduced FcepsilonRI-mediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy.The Role of Type 2 Inflammation in the Pathogenesis of Asthma Exacerbations.Clinical effectiveness and safety of montelukast in asthma. What are the conclusions from clinical trials and meta-analyses?Accelerated dissociation of IgE-FcεRI complexes by disruptive inhibitors actively desensitizes allergic effector cells.Omalizumab: the evidence for its place in the treatment of allergic asthma Omalizumab in the treatment of asthma.T regulatory cells control antigen-induced recruitment of mast cell progenitors to the lungs of C57BL/6 mice Longitudinal changes in asthma control with omalizumab: 2-year interim data from the EXCELS Study.Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.Omalizumab: Practical considerations regarding the risk of anaphylaxis.Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production.Omalizumab in children.Omalizumab in the management of patients with allergic (IgE-mediated) asthma.

P2860

Q24186306-E825F498-92A3-4C51-B6D3-6C796598B5F0 Q24201145-26F59E8B-ECB9-4B50-B032-6CC2F70EBCB6 Q24246484-28D52D71-39E2-43D7-9F66-19609C7075CF Q24247152-F436ECCE-4F24-48A1-8095-B4B75E470B4C Q24599763-9D261153-8564-429D-9281-2D3B657581BB Q26745901-0E4D9C6E-94A2-4AE0-BF63-483D0D3CE0E3 Q26766294-EBC25026-38A8-4D67-BF1B-A5B3326AB382 Q26851613-8A7C6EE6-AA47-4823-8884-ACD7E56D762E Q26998727-693EBE66-3701-4510-B4F8-FFD2C29D5892 Q27689386-ACE786A1-5092-46F6-9F80-32BCFB8AC693 Q28073074-A6588905-712F-4C17-90CE-FBE242559171 Q28077546-7D5C28E8-5AFC-49E3-BDA8-C595253BCCD5 Q28079238-97DA2FF8-7069-4A30-87EA-BE9FB1CBCBF7 Q28085614-F670CD4B-2660-4F48-A356-DC662339F1D4 Q28270037-A3E8005E-72C8-4578-BC77-8277125F9681 Q30244169-A1129C76-1A3E-4D91-9C49-1C30ED37913B Q30276175-58929C25-23E8-4C76-B8E4-5B07697328A4 Q30360362-5103A20A-5733-4179-AD7A-357AF0098392 Q30421935-F425AB2C-699F-4A6C-9C4E-42D5412BBB53 Q30433722-182E4BE7-7F9D-48DD-842C-1DC9C2D91CA3 Q30443366-E0880E54-03AD-42E7-A4AB-14830EBDA106 Q30488473-CC65B131-AC54-46BB-B4A9-A9C388272CCF Q30801642-B55453B6-0BC6-4037-B23A-6B98DEF0EAA5 Q33366487-4654A4C0-85F3-40A3-AABE-1B5D2E3C3499 Q33568644-8100AC80-15CE-4A95-981C-F652CC00FD6E Q33591890-5C6A3AF7-B9DF-403E-B79B-F3A4B25CCB9C Q33622564-4B370EA7-3542-494A-A015-671F4BD1DE0A Q33785112-4EF797FF-85FE-4768-AE03-3BB33D6E900D Q33786076-0A7FFB62-9A7F-4A0D-A5FA-5CAB1BF63591 Q33838131-A3C1CC07-5449-4772-9320-15DFEBFD8EAB Q33850604-B4BCFD03-226E-4F2A-B712-5DAC8A55DCC0 Q33973970-267CBC94-4171-4900-856E-044CE28394D8 Q34029374-BB99273C-3E14-4010-B0E8-A3FF5C26DDE4 Q34180508-A72555E4-7C53-4D2A-BA89-8E6AEBB59956 Q34336901-D7C5AE8A-018C-482C-86C3-BA4FF14CCFF3 Q34412092-089B9606-3D84-4CFF-A3AD-40B05431380B Q34426639-7968FBC1-2C32-476F-8C9A-A2537B0EA117 Q34427691-44E17ED3-4FDC-4473-9750-4C36176264CD Q34604574-A1005949-CFA6-41C3-A95D-4DD432B397BB Q34623856-DC520933-C129-4918-AB3E-997694B0C3F8

P2860

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.

http://www.wikidata.org/entity/Q43701894

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh-hant

name

Omalizumab, anti-IgE recombina ...... ent of severe allergic asthma.

@en

Omalizumab, anti-IgE recombina ...... ent of severe allergic asthma.

@nl

type

label

Omalizumab, anti-IgE recombina ...... ent of severe allergic asthma.

@en

Omalizumab, anti-IgE recombina ...... ent of severe allergic asthma.

@nl

prefLabel

Omalizumab, anti-IgE recombina ...... ent of severe allergic asthma.

@en

Omalizumab, anti-IgE recombina ...... ent of severe allergic asthma.

@nl

P1433

Q43701894-C4B5BFE6-06BC-4607-B4C9-06EEB6F8D03E

P1476

Q43701894-E8AD5A19-EA22-4230-8E50-0B1981DAF305

P2093

Q43701894-0C8BE57F-A58D-42F8-9B40-7E49D54D5D12

Q43701894-17E43E5F-BF85-4A1B-A632-D0C09A9B008A

Q43701894-3201FFA4-064F-43D2-8693-3FA3C387C358

Q43701894-54DDEE45-5247-4F72-9085-5BEB1F3E854E

Q43701894-65F2DF08-2414-4CBB-8857-036BA93D5923

Q43701894-81529FF4-B1C8-4B85-A30D-31E3897AB108

Q43701894-9DEB8E2D-59E1-4DFA-B8CA-03D9703B3050

Q43701894-DE1F8120-953E-49F8-8F55-8BF195F4FF0C

P304

Q43701894-10D12724-E0E2-43D6-AEB9-918EF7C407EF

P31

Q43701894-2BF4AA1D-710C-4DBB-8E5A-575D4F1287ED

P356

Q43701894-AE0F65B0-E5FC-413B-8462-CA3E1BB92C2C

P407

Q43701894-643D1874-E70C-4423-A963-59460F413CFE

P433

Q43701894-99498F21-9F70-42F1-BE78-DCD9365632C3

P478

Q43701894-FFC0A1B0-7F58-4B0F-851E-A19F2E59CA0C

P577

Q43701894-CAD2E2F6-3FD7-4279-B2C7-EEE3318A60C6

P698

Q43701894-E54390B0-0A2B-49E1-9725-69301768A82A

P921

Q43701894-1795C5CE-EBCB-489D-B5BD-EC8E3ECF5711

Q43701894-90A7DB6D-9D1F-42C8-AE42-8DE7AA2365DE

P356

MAI.2001.117880

P1433

The Journal of Allergy and Clinical Immunology

P1476

Omalizumab, anti-IgE recombina ...... ent of severe allergic asthma.

@en

P2093

Busse W

http://www.w3.org/2001/XMLSchema#string

Cioppa GD

http://www.w3.org/2001/XMLSchema#string

Corren J

http://www.w3.org/2001/XMLSchema#string

Fowler-Taylor A

http://www.w3.org/2001/XMLSchema#string

Gupta N

http://www.w3.org/2001/XMLSchema#string

Lanier BQ

http://www.w3.org/2001/XMLSchema#string

McAlary M

http://www.w3.org/2001/XMLSchema#string

van As A

http://www.w3.org/2001/XMLSchema#string

P304

184-190

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1067/MAI.2001.117880

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P577

2001-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11496232

http://www.w3.org/2001/XMLSchema#string

P921